NSF International and Novateur: Wondfo COVID-19 Antibody Test Meets WHO TPP “Desirable” Criteria
March 03,2021 (Edit) Wondfo
Wondfo COVID-19 antibody testwas identified to meet WHO TPP “desirable” criteria in the aspects of clinical specificity and sensitivity, and time to results by researchers at NSF International and Novateur Ventures.
NSF International and Novateur Ventures conducted a study to identify top-performing POCTs on the market based on the recently published World Health Organization (WHO) Target Product Profile (TPP) criteria, in order to help communities and healthcare systems to make selection and procurement of an appropriate test for specific use case easy.
After screening for more than 1,100 independently assessed, point-of-care COVID-19 tests, Wondfo antibody test stood out in the clinical specificity and sensitivity, and time to results (as shown in the below figures).
(Note: Short vertical lines: calculated clinical sensitivity; Blue line: WHO TPP “acceptable” threshold; Red line: WHO TPP “desirable” threshold.)
(Note: Short vertical lines: calculated clinical specificity; Blue line: WHO TPP “acceptable” threshold; Red line: WHO TPP “desirable” threshold.)
(Note: Blue line: WHO TPP “acceptable” threshold; Red line: WHO TPP “desirable” threshold.)
Wondfo's antibody tests in helping curb the COVID-19 pandemic
Wondfo 2019-nCoV antibody test (lateral flow method)is an immunochromatographic assay for the rapid, qualitative detection of 2019-nCoV IgG/IgM antibodies in human whole blood, serum, or plasma, indicating recent or past infection. It is easy to use and delivers results in 15 minutes, reliable and fast.
The tests have been widely recognized around the world. Last year, studies from Brown University and the University of California showed that Wondfo's antibody test achieved the highest sensitivity and specificity among all the tests evaluated. Researchers and hospital labs in Brazil, France, and Australia reached the same conclusions and recommended the tests in national and regional testing programs.
In Spain, Brazil, Ireland, and Indonesia, Wondfo's antibody tests have been selected as the main test assays by healthcare authorities in their national pandemic response. Wondfo's tests were used by the Brazilian Ministry of Health in population-based surveys in 133 sentinel cities to help make more informed decisions on preventive policies and health system preparedness at the state level.
The tests were also used in a Brazilian study of COVID-19 in children to detect if a child has a post-infectious syndrome caused by an infection.
Testing is key to beating the COVID-19 pandemic and allowing society and the economy to return to normal function. That’s why Wondfo, as China’s POCT leader with many years of experience in diagnostics, has been working across the company and leveraging all resources since the outbreak to develop tests to help bring the global pandemic under control.
As of today, Wondfo has supplied more than 50 million COVID-19 antibody tests in 93 countries since the beginning of the pandemic. Wondfo will continue to support the global community by ensuring continued access to reliable tests.
About NSF International
NSF International is an independent, global public health organization that has been dedicated to protecting and improving global human health since 1944.
It facilitates the development of public health standards, test, audit, and certify products and services. And It has ISO/IEC 17025-accredited, state-of-the-art global laboratories to provide a wide range of testing, certification, and technical services as well as human health risk assessments.
Guangzhou Wondfo Biotech Co., Ltd., has been focusing on the R&D, production, sales, and service of point-of-care testing (POCT) products and providing customers with professional rapid diagnosis and chronic disease management solutions since founded in 1992.
Here, everything we do is to safeguard the health and improve the lives of people worldwide. With this in mind, we’ll continue to innovate and shape the future of POCT and healthcare.